Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ODC1 | P11926 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100630 | 1.00 | DUT (0.37) | DUTDNM1CA12CA1CA2 | |
| SCHEMBL8057981 | 1.00 | DUT (0.37) | DUTDNM1CA12CA1CA2 | |
| SCHEMBL28903381 | 1.00 | DUT (0.37) | DUTDNM1CA12CA1CA2 | |
| SCHEMBL1785391 | 0.98 | DUT (0.38) | DUTDNM1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL29281207 | 0.96 | DUT (0.37) | DUTDNM1ODC1 | |
| SCHEMBL1038400 | 0.91 | ODC1 (0.42) | DUTODC1 | |
| SCHEMBL9007756 | 0.89 | DUT (0.42) | DUT | |
| SCHEMBL14245094 | 0.89 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.89 | DUT (0.42) | DUT | |
| SCHEMBL8063404 | 0.86 | DUT (0.43) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064944-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-02-27 | — | — | US | disclosed |
| WO-2025021829-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023086028-A2 | ALLENAMIDE LINKERS FOR ANTIBODY-DRUG CONJUGATE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-05-19 | — | — | WO | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016073652-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | UNITHER VIROLOGY, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| US-6114518-A | Synthesis and use of labelled phosphoramidite compositions | BECTON, DICKINSON AND COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-5210203-A | Sulfonamide-derivative compounds for tagging nucleic acid probes | SISKA DIAGNOSTICS, INC. (US) | 1993-05-11 | — | — | US | disclosed |
| US-5130446-A | Derivatives of fluoroscein or rhodamine | SISKA DIAGNOSTICS, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| US-4833251-A | FLUORESCENT COMPOUNDS | SISKA DIAGNOSTICS, INC. (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0209996-A2 | Nucleic acid probes comprising N4 -(substituted amino)cytidines | SISKA DIAGNOSTICS,INC. (US) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064944-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | SNRPE, EXOSC5, DIS3 | DUT 108/4885DNM1 369/4885CA12 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.